The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes

• Published in: JCI insight 2024-12, Vol.9 (24)
• Main Authors: Alvarez, Fernando, Acuff, Nicole V, La Muraglia, 2nd, Glenn M, Sabri, Nazila, Milla, Marcos E, Mooney, Jill M, Mackey, Matthew F, Peakman, Mark, Piccirillo, Ciriaco A
• Format: Article
• Language: English
• Subjects: Animals; Autoimmunity - drug effects; CD8-Positive T-Lymphocytes - drug effects; CD8-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - metabolism; Diabetes Mellitus, Type 1 - immunology; Diabetes Mellitus, Type 1 - metabolism; Disease Models, Animal; Female; Interleukin-1 Receptor-Like 1 Protein - metabolism; Interleukin-10 - immunology; Interleukin-10 - metabolism; Interleukin-2 - analogs & derivatives; Interleukin-2 - immunology; Interleukin-2 - metabolism; Interleukin-2 Receptor alpha Subunit - metabolism; Interleukin-33 - immunology; Interleukin-33 - metabolism; Islets of Langerhans - drug effects; Islets of Langerhans - immunology; Islets of Langerhans - metabolism; Mice; Mice, Inbred NOD; Recombinant Proteins; Signal Transduction - drug effects; T-Lymphocytes, Regulatory - drug effects; T-Lymphocytes, Regulatory - immunology; Th1 Cells - drug effects; Th1 Cells - immunology
• ISSN: 2379-3708; 2379-3708
• DOI: 10.1172/jci.insight.182064

Deficits in IL-2 signaling can precipitate autoimmunity by altering the function and survival of FoxP3+ regulatory T cells (Tregs) while high concentrations of IL-2 fuel inflammatory responses. Recently, we showed that the non-beta IL-2 SYNTHORIN molecule SAR444336 (SAR'336) can bypass the induction of autoimmune and inflammatory responses by increasing its reliance on IL-2 receptor α chain subunit (CD25) to provide a bona fide IL-2 signal selectively to Tregs, making it an attractive approach for the control of autoimmunity. In this report, we further demonstrate that SAR'336 can support non-beta IL-2 signaling in murine Tregs and limit NK and CD8+ T cells' proliferation and function. Using a murine model of spontaneous type 1 diabetes, we showed that the administration of SAR'336 slows the development of disease in mice by decreasing the degree of insulitis through the expansion of antigen-specific Tregs over Th1 cells in pancreatic islets. Specifically, SAR'336 promoted the differentiation of IL-33-responsive (ST2+), IL-10-producing GATA3+ Tregs over other Treg subsets in the pancreas, demonstrating the ability of this molecule to further orchestrate Treg adaptation. These results offer insight into the capacity of SAR'336 to generate highly specialized, tissue-localized Tregs that promote restoration of homeostasis during ongoing autoimmune disease.